Denali Therapeutics Sees Positive Data in Trial for Enzyme Replacement Therapy

Denali Therapeutics Inc. said it saw positive interim data from a Phase 1/2 study evaluating DNL310, an investigational brain-penetrant enzyme replacement therapy intended to treat central nervous system and peripheral manifestations of Hunter syndrome.